CIP2A and non-small cell lung carcinoma: Therefore, investigating the mechanisms of CIP2A stabilization in a range of NSCLC cell lines adapted to EGFR tyrosine kinase inhibitors is needed to contribute to a better understanding of clonal heterogeneity.